The Effect of Mild Cognitive Impairment Management Program on Traditional Korean Medicine in a Public Health Center

Article information

J Korean Med. 2013;34(3):106-118
Publication date (electronic) : 2013 September 30
doi : https://doi.org/10.13048/jkm.13016
Department of Traditional Korean Medicine of Uijeongbu-city Public Health Center
Correspondence to: 김경한(Kyeong Han Kim), 경기도 의정부시 의정부시보건소, Tel : +82-31-850-5883, Fax : +82-31-873-7719, E-mail : solip922@hanmail.net
Received 2013 July 04; Revised 2013 September 02; Accepted 2013 September 11.

Abstract

Objectives:

The aim of this study was to evaluate the effect of a mild cognitive impairment (MCI) management program on traditional Korean medicine in a public health center.

Methods:

In order to examine the effect of the MCI management program, we investigated MCI patients who participated in the program. MCI patients were treated with Jodeung-san (JDS) or Dangguijagyag-san (DGJYS) for 6 weeks. Mini Mental State Examination-Dementia Screening (MMSE-DS), Geriatric Quality of Life-Dementia (GQOL-D), Geriatric Depression Scale in Korea (GDS-K), and biochemical examination of blood were conducted at intervals of 6 weeks. A satisfaction survey was collected after this program.

Results:

MMSE-DS mean score increased significantly, by 4.09 (p=0.000) in the JDS group and by 4.15 (p=0.000) in the DGJYS group. GQOL-D mean score also increased significantly, by 5.90 (p=0.000) in the JDS group and by 5.07 (p=0.000) in the DGJYS group. GDS-K mean score decreased significantly, by 10.63 (p=0.000) in the JDS group and by 9.69 (p=0.000) in the DGJYS group. MMSE-DS, GDS-K and GQOL-D scores were not significantly different between the JDS and DGJYS groups. All of the participants were satisfied with the program, and 90% of the participants expressed a high intention to participate in the program again.

Conclusions:

Both Jodeung-san and Dangguijagyag-san treatment showed improvement on cognitive function, depression and quality of life in this program. Additional studies with more subjects will be required to prove credibility and validity more clearly.

Fig. 1.

Change of MMSE-DS Scores with the Program

Fig. 2.

Change of GDS-K Scores with the Program

Fig. 3.

Change of GQOL-D Scores with the Program

Fig. 4.

Satisfaction after the Program

Fig. 5.

Changes in perception of MCI after the Program

Fig. 6.

Re-participation Intention after the Program

Composition of JDS

Composition of DGJYS

Charateristics of Subjects

Change of MMSE-DS Scores with the Program

Change of GDS-K Scores with the Program

Change of GQOL-D Scores with the Program

Difference of Scores between JDS and DGJYS Group

Change of biochemical examination of blood with the Program

References

1. Statistics Korea. Future Population Projection Statistics Korea; 2012.
2. Ministry of Health & Welefare. Survey of Dementia Prevalence Rate Ministry of Health & Welefare; 2008.
3. Ku BD, Kim SG, Lee JY, Park KH, Shin JH, Kim KK, et al. Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. J Korean Med Assoc 2011;54(8):861–875.
4. Choi KG. Neuropathology of MCI-View from Relationships with Aging and Alzheimer’s Disease-. Dementia and Neurocognitive Disorders 2003;2:101–107.
5. Petersen RC, Doody R, Kurz , Mohs RC, Morris JC, Rabins PV, et al. Current Concepts in Mild Cognitive Impairment. Arch Neurol 2001;58:1985–1992.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997;9(1):65–69.
7. Shah Y, Tangalos EG, Petersen RC. Mild cognitive impairment. When is it a precursor to Alzheimer’s disease? Geriatrics 2000;55:65–68.
8. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the eldery: predictiors of dementia. Neurology 1991;41:1006–1009.
9. Ministry of Health & Welefare. National Epidemiologic Investigation Ministry of Health & Welefare; 2008.
10. Han CS, Lee JY, Lee DW, Ryu SH, Lee KJ, Kim JH, et al. Development of Hybrid Model for Integrating Management of Geriatric Depression and Dementia in Urban Area. J Korean Geriatr So 2006;10(2):104–114.
11. John KA, Heather BB. The sensitivity of the Beck Depression Inventory to changes of symptomatology. Br J Psychiatry 1974;125:184–185.
12. Peter R. Ageing and the brain. Postgrad Med J 2007;82:84–88.
13. Heo EJ, Kang JS, Kang HW, Jeon WK. Evaluation on the Quality of Research Field with Traditional Herbal Prescriptions for Dementia Therapy. J of Oriental Neuropsychiatry 2012;23(1):93–114.
14. Murakami Y, Zhao Q, Harada K, Tohda M, Watanabe H, Matsumoto K. Choto-san, a Kampo formula, improves chronic cerebral hypo-perfusion-induced spatial learning deficit via stimulation of myscarinic M1 receptor. Pharmacology Biochemistry and Behavior 2005;81(3):616–625.
15. Koichi Y, Yutaka S, Etsuro H, Nobuyasu S, Hirozo G, Owao S, et al. Protective effects of Choto-san and hooks and stems of Uncaria sinesis against delayed neuronal death after transient forebrain ischemia in gerbil. Phytomedicine 2004;11:478–489.
16. Watanabe H, Zhao Q, Matsumoto K, Tohda M, Murakami Y, Zhang SH, et al. Pharmacological evidence for antidementia effect of Chotosan(Guteng-san), a traditional Kampo medicine. Pharamacol Biochem Behav 2003;75(3):635–643.
17. Mizushima Y, Kan S, Yoshida S, Irie Y, Urata Y. Effect of Choto-san a Kampo medicine, on impairment of passive avoidance performance in senescence accelerated mouse(SAM). Phytotherapy research 2003;17:542–545.
18. Matsuoka T, Narumoto J, Shibata K, Okamura A, Taniguchi S, Kitabayashi Y, et al. Effect of Toki-Shakuyaku-San on Regional Cerebral Blood Flow in Patients with Mild Cognitive Impairment and Alzheimer’’s Disease. Evi-Based Com and Alt Med 2012;
19. Inanaga K, Dainoson K, Ninomiya Y, TAkii O, Omaru M, Tanaka T, et al. Effects of Toko-Shakuyaku-San in Patients with Senile Cognitive Disoreders. Progress in Medicine 1996;16:293–300. 1996.
20. Iwasaki K, Satoh-Nakaqawa T, Maruyama M, Monma Y, Tomita N, Tanji H, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symtoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66(2):248–252.
21. Folstein MF, Folstein SE. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J of Psych Res 1975;12:189–198.
22. Park JH, Kwon YC. Standardization of Korean of the Mini-Mental State Examination (MMSE-K) for Use in the Elderly-Part II. Diagnostic Validity. J Korean NeuroPsychiatric Assoc 1989;28:508–513.
23. Kang YW, Na DY, Han SH. A Validity Study on the Korean Mini-Mental State Examination (K-MMSE) in Dementia Patients. J Korean Neurol Assoc 1997;15:300–307.
24. Lee JH, Lee KU, Lee DY, Kim KW, Kim JH, Lee KH, et al. Development of the Korean version of the consortium to establish a registry for alzheimer’s disease assessment packet (CERAD-K): clinical and neuro-psychological assessment batteries. J Gerontology Series B: Psychological Sciences and Social Sciences 2002;57(1):47–53.
25. Han JW, Kim TH, Joo JH, Park JH, Kim JR, Yoo SH, et al. A Normative Study of the Mini-Mental State Examination for Dementia Screening (MMSE-DS) and Its Short form (SMMSE-DS) in the Korean Elderly. J Korean Geriatr Psychiatry 2010;14(1):27–37.
26. Lee HS, Kim JH, Ko HJ, Ku HM, Kwon EJ, Shin JY, et al. The Standardization of the Geriatric Quality of Life scale-Dementia(GQOL-D). J Korean Geriatr Soc 2004;8(3):151–164.
27. Ki BS, Lee CW. A Preliminary Study for the Standardization of Geriatric Depression Scale in Korea. J Korean NeuroPsychiatric Assoc 1995;129:1875–1885.
28. Ministry of Health & Welefare. Direction for Korean Medicine Health Promotion Program in 2013 Ministry of Health & Welefare; 2012.
29. Gyeonggi Statistical Information Service. Population Statistics Gyeonggi Statistical Information Service; 2012.
30. Choi SH, Na DL, Oh KM, Park BJ. A Short form of the Samsung Dementia Questionnaire (S-SDQ): development and cross-validation. J Korean Neurol Assoc 1997;17(2):253–258.
31. Galasko D, Kauber MR, Hoftetter R, Salmon DP, Lasker B, Thal LJ. The mini-mental state examination in the elderly diagnosis of Alzheimer’ disease. Arch Neurol 1990;47(1):49–52.
32. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 1999;56(7):857–862.
33. Lee KS, Jung HK, Oh BH, Hong CH. Comparison of the Validity of Screening Tests for Dementia and Mild Cognitive Impairment of the Elderly in a Community K-MMSE, MMSE-K, MMSE-KC, and K-HDS. J Korean NeuroPsychiatric Assoc 2009;48(2):61–69.
34. Nasreddine ZS, Phillips NA, Béirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J American Geriatrics Society 2005;53(4):695–699.

Article information Continued

Fig. 1.

Change of MMSE-DS Scores with the Program

Fig. 2.

Change of GDS-K Scores with the Program

Fig. 3.

Change of GQOL-D Scores with the Program

Fig. 4.

Satisfaction after the Program

Fig. 5.

Changes in perception of MCI after the Program

Fig. 6.

Re-participation Intention after the Program

Table 1.

Composition of JDS

Composition Amount Unit
JDS extract contain dried extract of the following mixed crude drugs 1.5 g
Gypsum 1.7 g
Uncaria Hook 1.0 g
Citrus Unshiu Peel 1.0 g
Ophiopogon Tuber 1.0 g
Pinellia Tuber 1.0 g
Poria Sclerotium 1.0 g
Chrysanthemum Flower 0.7 g
Ginseng 0.7 g
Saposhnikovia Root 0.7 g
Glycyrrhiza 0.3 g
Ginger 0.3 g
Lactose Hydrate 0.9875 g
Magnesium Stearate 0.0125 g

Total 2.5 g

Table 2.

Composition of DGJYS

Composition Amount Unit
DGJYS extract contain dried extract of the following mixed crude drugs 1.0 g
Peony Root 1.0 g
Atractylodes Lancea Rhizome 1.0 g
Alisma Rhizome 1.0 g
Poria Sclerotium 1.0 g
Cnidium Rhizome 0.75 g
Japanese Angelica Root 0.75 g
Lactose Hydrate 0.86562 g
Magnesium Stearate 0.00938 g

Total 1.875 g

Table 3.

Charateristics of Subjects

Variables JDS Group DGJYS Group Total

N % N % N %
Sex Male 3 27.3 2 15.4 5 20.8
Female 8 72.7 11 84.6 19 79.2
Total 11 100 13 100 24 100

Age 73.91±2.98 73.92±3.77 73.92±3.17
Education level 4.55±4.01 2.85±3.98 3.63±3.94
MMSE-DS 20.55±2.62 19.23±2.83 19.83±2.76
GDS-K 22.27±3.95 21.23±5.57 21.71±4.82
GQOL-D 21.55±3.11 20.85±3.74 21.17±3.41

Table 4.

Change of MMSE-DS Scores with the Program

MMSE-DS Mean Std. Deviation t Sig.(2-tailed)

JDS DGJYS Total JDS DGJ YS Total JDS DGJYS Total JDS DGJYS Total
Orientation Before 8.45 7.69 8.04 1.44 1.70 1.61 −2.14 −2.41 −3.29 0.058 0.033* 0.003**
After 9.45 8.85 9.12 0.69 1.07 0.95
Attention Before 1.64 1.08 1.33 1.43 1.32 1.37 −2.89 −3.09 −4.29 0.016* 0.009** 0.000**
After 2.55 2.15 2.33 1.04 1.86 1.52
Memory Before 4.18 4.15 4.17 0.98 0.90 0.92 −1.17 −2.21 −2.4 0.267 0.047* 0.024*
After 4.55 4.69 4.63 1.04 0.95 0.97
Language Before 4.00 4.46 4.25 0.77 0.78 0.79 −7.06 −3.86 −7.0 0.000** 0.002** 0.000**
After 5.45 5.38 5.42 0.69 0.65 0.65
Visuospatial ability Before 0.45 0.15 0.29 0.52 0.38 0.46 −1.49 −1.48 −2.15 0.167 0.165 0.043*
After 0.64 0.31 0.46 0.50 0.48 0.51
Judgement Before 1.82 1.77 1.79 0.40 0.44 0.41 −1.49 −1.90 −2.46 0.167 0.082 0.022*
After 2.00 2.00 2.00 0.00 0.00 0.00
Total Before 20.55 19.23 19.83 2.62 2.83 2.76 −5.59 −7.22 −9.21 0.000** 0.000** 0.000**
After 24.64 23.38 23.96 1.75 1.80 1.85
*

p<0.05,

**

p<0.01

Table 5.

Change of GDS-K Scores with the Program

GDS-K
Mean Std. Deviation t Sig.(2-tailed)
JDS Group Before 22.27 3.95 9.92 0.000**
After 11.64 4.57
DGJYS Group Before 21.23 5.57 8.00 0.000**
After 11.54 4.94
Total Before 21.71 4.82 12.53 0.000**
After 11.58 4.67
*

p<0.05,

**

p<0.01

Table 6.

Change of GQOL-D Scores with the Program

GQOL-D
Mean Std. Deviation t Sig.(2-tailed)
JDS Group Before 21.55 3.11 −7.26 0.000**
After 27.45 3.88
DGJYS Group Before 20.85 3.74 −5.06 0.000**
After 25.92 4.01
Total Before 21.17 3.41 −8.38 0.000**
After 26.63 3.94
*

p<0.05,

**

p<0.01

Table 7.

Difference of Scores between JDS and DGJYS Group

Mean Difference Std. Deviation F Sig.(2-tailed)
MMSE-DS JDS Group 4.09 2.43 0.097 0.758
DGJYS Group 4.15 2.08
GQOL-D JDS Group 5.91 2.70 0.028 0.868
DGJYS Group 5.08 3.62
GDS-K JDS Group −10.64 3.56 0.215 0.648
DGJYS Group −9.69 4.37
*

p<0.05,

**

p<0.01

Table 8.

Change of biochemical examination of blood with the Program

JDS Group DGJYS Group

M±SD Sig.(2-tailed) M±SD Sig.(2-tailed)
AST Before 27.09±10.92 0.592 25.31±7.81 0.335
After 25.73±18.82 23.15±3.76
ALT Before 18.82±9.52 0.471 19.31±7.34 0.829
After 19.82±6.43 18.85±5.51
rGPT Before 42.82±43.62 0.913 36.31±46.00 0.114
After 41.45±60.26 33.54±44.58
BUN Before 16.06±3.29 0.260 14.55±3.74 0.472
After 18.11±6.20 15.54±3.05
Creatinine Before 0.94±0.25 0.736 0.84±0.12 0.223
After 0.92±0.30 0.78±0.18
Uric acid Before 5.63±1.45 0.346 5.13±1.18 0.069
After 5.30±0.82 4.84±1.01
*

p<0.05,

**

p<0.01